

Clive S Zent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/526017/publications.pdf>

Version: 2024-02-01

127
papers

3,255
citations

196777

29
h-index

175968

55
g-index

127
all docs

127
docs citations

127
times ranked

4036
citing authors

#	ARTICLE	IF	CITATIONS
1	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , 2018, 103, 874-879.	1.7	329
2	Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. <i>Blood</i> , 2007, 109, 405-411.	0.6	278
3	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	0.6	193
4	Diffuse large B-cell lymphoma (DLBCL) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. <i>British Journal of Haematology</i> , 2013, 162, 774-782.	1.2	187
5	CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. <i>British Journal of Haematology</i> , 2008, 140, 537-546.	1.2	152
6	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	1.7	135
7	The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. <i>British Journal of Haematology</i> , 2008, 141, 615-621.	1.2	101
8	The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. <i>Cancer</i> , 2010, 116, 2201-2207.	2.0	89
9	Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early/intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. <i>Leukemia Research</i> , 2008, 32, 1849-1856.	0.4	85
10	Autoimmune Complications in Chronic Lymphocytic Leukaemia (CLL). <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 47-59.	0.7	84
11	Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 211-217.	0.6	82
12	Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007, 139, 398-404.	1.2	76
13	Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. <i>Leukemia and Lymphoma</i> , 2009, 50, 1261-1268.	0.6	69
14	Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. <i>Cancer</i> , 2008, 113, 2110-2118.	2.0	67
15	Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) have a Markedly Increased Rate of Second Malignancy, which is the Most Common Cause of Death. <i>Leukemia and Lymphoma</i> , 2004, 45, 507-513.	0.6	66
16	Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity. <i>FEBS Journal</i> , 2017, 284, 1021-1039.	2.2	61
17	Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. <i>Leukemia Research</i> , 2004, 28, 495-507.	0.4	58
18	Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. <i>Leukemia and Lymphoma</i> , 2018, 59, 625-632.	0.6	57

#	ARTICLE	IF	CITATIONS
19	Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. <i>Cancer Immunology Research</i> , 2018, 6, 1150-1160.	1.6	57
20	What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. <i>British Journal of Haematology</i> , 2016, 174, 835-846.	1.2	55
21	Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018, 93, 1394-1401.	2.0	52
22	Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions. <i>Journal of Immunology</i> , 2016, 197, 1762-1775.	0.4	50
23	Induced Resistance to Ofatumumab-Mediated Cell Clearance Mechanisms, Including Complement-Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2014, 192, 1620-1629.	0.4	48
24	miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. <i>Blood</i> , 2018, 132, 2389-2400.	0.6	45
25	Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. <i>Leukemia and Lymphoma</i> , 2012, 53, 2218-2227.	0.6	42
26	Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2079-2084.	0.6	42
27	CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. <i>Haematologica</i> , 2019, 104, 1841-1852.	1.7	38
28	Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. <i>British Journal of Haematology</i> , 2013, 163, 326-333.	1.2	35
29	Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. <i>American Journal of Hematology</i> , 2014, 89, 757-765.	2.0	32
30	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2007, 110, 121-121.	0.6	31
31	CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma. <i>Leukemia Research</i> , 2010, 34, 1235-1238.	0.4	30
32	CD5-positive chronic B-cell lymphoproliferative disorders: Diagnosis and prognosis of a heterogeneous disease entity. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S35-41.	0.7	29
33	Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma. <i>Leukemia</i> , 2021, 35, 1788-1791.	3.3	29
34	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	3.3	28
35	Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells. <i>Molecular Immunology</i> , 2016, 70, 13-23.	1.0	26
36	Management of Chronic Lymphocytic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 164-175.	1.8	24

#	ARTICLE	IF	CITATIONS
37	Monoclonal antibody (mAb)-based cancer therapy. <i>Oncolimmunology</i> , 2012, 1, 959-961.	2.1	21
38	Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. <i>Leukemia and Lymphoma</i> , 2015, 56, 2373-2378.	0.6	20
39	Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. <i>Journal of Clinical Investigation</i> , 2008, 118, 306-315.	3.9	20
40	Vancomycin-induced thrombocytopenia. , 1999, 62, 122-123.		19
41	Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 119-124.	0.9	18
42	Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance. <i>Blood</i> , 2020, 136, 2065-2079.	0.6	18
43	Management of melanoma in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2018, 71, 43-46.	0.4	17
44	Localized herpes simplex lymphadenitis mimicking large-cell (Richter's) transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2001, 68, 287-291.	2.0	16
45	FISH Scoring for CLL: Comparison of Methods That Assess Round Versus Non-Round Nuclei,. <i>Blood</i> , 2011, 118, 3538-3538.	0.6	16
46	Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication. <i>Leukemia and Lymphoma</i> , 2015, 56, 311-314.	0.6	15
47	Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.. <i>Blood</i> , 2005, 106, 707-707.	0.6	14
48	Management of autoimmune cytopenia complicating chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 863-864.	0.6	13
49	A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOGâ€ACRIN cancer research group (E1908). <i>American Journal of Hematology</i> , 2016, 91, 308-312.	2.0	13
50	Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. <i>Leukemia and Lymphoma</i> , 2011, 52, 1425-1434.	0.6	12
51	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study. <i>Leukemia and Lymphoma</i> , 2016, 57, 1585-1591.	0.6	11
52	Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9. <i>Clinical Immunology</i> , 2017, 181, 24-28.	1.4	11
53	Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment. <i>Leukemia and Lymphoma</i> , 2020, 61, 1627-1635.	0.6	11
54	Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. <i>Leukemia and Lymphoma</i> , 2013, 54, 476-482.	0.6	10

#	ARTICLE	IF	CITATIONS
55	Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia. <i>Current Oncology Reports</i> , 2004, 6, 348-354.	1.8	9
56	High-resolution quantification of discrete phagocytic events by live cell time-lapse high-content microscopy imaging. <i>Journal of Cell Science</i> , 2020, 133, .	1.2	9
57	Initial treatment of B-cell prolymphocytic leukemia with ibrutinib. <i>American Journal of Hematology</i> , 2020, 95, E108-E110.	2.0	8
58	A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 41-42.	0.6	6
59	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).. <i>Blood</i> , 2006, 108, 530-530.	0.6	6
60	Targeted therapy for treatment of patients with classical hairy cell leukemia. <i>Leukemia Research</i> , 2021, 102, 106522.	0.4	5
61	Initial Presentation and Prognostic Factors in 286 Patients with T-Cell Large Granular Lymphocyte Leukemia.. <i>Blood</i> , 2006, 108, 300-300.	0.6	5
62	Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy. <i>Blood</i> , 2008, 112, 43-43.	0.6	5
63	Hodgkin Transformation Of Chronic Lymphocytic Leukemia (CLL): Mayo Clinic Experience. <i>Blood</i> , 2013, 122, 1642-1642.	0.6	5
64	Multiple B cell malignancies in patients with chronic lymphocytic leukemia: epidemiology, pathology, and clinical implications. <i>Leukemia and Lymphoma</i> , 2020, 61, 1037-1051.	0.6	4
65	Complement Activation in the Treatment of B-Cell Malignancies. <i>Antibodies</i> , 2020, 9, 68.	1.2	4
66	Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells. <i>Blood</i> , 2020, 136, 45-45.	0.6	4
67	Cell-mediated immunity in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 1775-1776.	0.6	3
68	Improving quality of life in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1247-1248.	0.6	3
69	CLL: an acquired immunodeficiency disease. <i>Blood</i> , 2016, 128, 1908-1909.	0.6	3
70	The Pentostatin, Cyclophosphamide, and Rituximab Regimen (PCR) Is Highly Active and Well Tolerated Regardless of Patient Age, Creatinine Clearance, and Performance Status: Analysis of a Multi-Center Phase II Trial.. <i>Blood</i> , 2006, 108, 36-36.	0.6	3
71	Correlates of anxiety and depression in chronic lymphocytic leukemia (CLL) survivors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 153-153.	0.8	3
72	Ibrutinib therapy for lymphoplasmacytic lymphoma. <i>American Journal of Hematology</i> , 2017, 92, E542-E544.	2.0	2

#	ARTICLE	IF	CITATIONS
73	Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy. <i>American Journal of Hematology</i> , 2020, 95, E16-E18.	2.0	2
74	Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL. <i>Blood</i> , 2011, 118, 3899-3899.	0.6	2
75	A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2007, 110, 124-124.	0.6	2
76	Cognitive function in chronic lymphocytic leukemia (CLL): Examining effects of disease, treatment, and inflammation. <i>Journal of Clinical Oncology</i> , 2019, 37, 11584-11584.	0.8	2
77	Update on monoclonal antibody therapy in chronic lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2004, 2, 107-13.	0.3	2
78	The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact. <i>Haematologica</i> , 2022, 107, 1460-1465.	1.7	2
79	The role of alemtuzumab in the treatment of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 175-176.	0.6	1
80	FISHing for answers in proliferation centers of chronic lymphocytic leukemia lymph nodes. <i>Leukemia and Lymphoma</i> , 2011, 52, 946-947.	0.6	1
81	Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). <i>Leukemia and Lymphoma</i> , 2020, 61, 1636-1644.	0.6	1
82	Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 598-605.	0.6	1
83	Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 4465-4467.	3.2	1
84	Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice. <i>Blood</i> , 2019, 134, 682-682.	0.6	1
85	Interphase Fluorescence In Situ Hybridization (FISH) with an IgH Probe Is Important in the Management of Patients with a Clinical Diagnosis of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2004, 104, 1919-1919.	0.6	1
86	Smudge Cells on Routine Blood Smear Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test. <i>Blood</i> , 2006, 108, 2785-2785.	0.6	1
87	CD5+ Chronic B-Cell Lymphoproliferative Disorders Could Contain a Novel Disease Entity. <i>Blood</i> , 2008, 112, 2065-2065.	0.6	1
88	Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). <i>Blood</i> , 2011, 118, 1790-1790.	0.6	1
89	Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab. <i>Blood</i> , 2011, 118, 2836-2836.	0.6	1
90	Axl Receptor Tyrosine Kinase Signaling Pathway and the p53 Tumor Suppressor Protein Exist In A Novel Regulatory Loop In B-Cell Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011, 118, 799-799.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.. Blood, 2007, 110, 337-337.	0.6	1
92	ATM Gene Point Mutation and Frameshift Mutation Are Found In High-Risk, Untreated Chronic Lymphocytic Leukemia Patients with Interstitial Deletion of Chromosome 11q and Uniparental Disomy of Chromosome 11q. Blood, 2010, 116, 2420-2420.	0.6	1
93	Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL,. Blood, 2011, 118, 3898-3898.	0.6	1
94	Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL).. Blood, 2011, 118, 4152-4152.	0.6	1
95	Diagnosis and management of complications of chronic lymphocytic leukemia/small lymphocytic lymphoma. Acta Haematologica Polonica, 2019, 50, 91-97.	0.1	1
96	Arrhythmia Burden in Patients with Indolent Lymphoma. Blood, 2020, 136, 6-7.	0.6	1
97	Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.. Journal of Clinical Oncology, 2022, 40, 7577-7577.	0.8	1
98	Detection of recurrent chromosomal defects in chronic lymphocytic leukemia/small lymphocytic lymphoma: Innovations and applications. Leukemia and Lymphoma, 2010, 51, 186-187.	0.6	0
99	Multi-parameter prognostication in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2011, 52, 1823-1824.	0.6	0
100	Infection in chronic lymphocytic leukemia: parsimony has its limits. Leukemia and Lymphoma, 2014, 55, 2683-2684.	0.6	0
101	Chronic lymphocytic leukemia and proteomics: protein profiles and links with disease progression still need validation. Leukemia and Lymphoma, 2016, 57, 985-986.	0.6	0
102	Monoclonal antibody therapy in chronic lymphocytic leukemia. Oncology Signaling, 2018, 1, 11-13.	0.2	0
103	Changing of the guard: Leukemia Research 2021. Leukemia Research, 2021, 100, 106510.	0.4	0
104	Loss of p53 Is Due to Rearrangements in a ~6,400 kb Region of Low Copy Repeats near the Centromere of Chromosome 17 in Chronic Lymphocytic Leukemia (B-CLL).. Blood, 2005, 106, 3255-3255.	0.6	0
105	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 5420-5420.	0.6	0
106	Submicroscopic Interstitial Deletions in 13q14 Are Detectable in Metaphase Cells by Fluorescence In Situ Hybridization (FISH) with D13S319 in Chronic Lymphocytic Leukemia (B-CLL).. Blood, 2005, 106, 3278-3278.	0.6	0
107	Whole Genome Copy Number Variation Analysis of Chronic Lymphocytic Leukemia (CLL) Cells From Early-Intermediate Stage, High Risk CLL Patients Prior to First Treatment Reveals New Loss of Heterozygosity and Duplication Events in the CLL Genome.. Blood, 2009, 114, 1265-1265.	0.6	0
108	Complex Interstitial Deletions of 11q and Copy-Neutral Loss of Heterozygosity of 11q Are Detected by Whole Genome Copy Number Variation Analysis of Early-Intermediate Stage, High Risk Chronic Lymphocytic Leukemia Patients.. Blood, 2009, 114, 1245-1245.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Vitamin D Insufficiency and Prognosis In Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 2408-2408.	0.6	0
110	Monoclonal and Polyclonal Serum Free Light Chains and Clinical Outcome In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 2409-2409.	0.6	0
111	Survival of Patients with Clinically Identified Monoclonal B-Cell Lymphocytosis (MBL) Relative to the Age and Sex Matched General Population. Blood, 2010, 116, 700-700.	0.6	0
112	Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. Blood, 2010, 116, 3115-3115.	0.6	0
113	CLL Cells From Subjects Treated with Rituximab and Alemtuzumab Can Lose Target Antigen and Develop Resistance to Mab-Mediated Complement Dependent Cytotoxicity. Blood, 2010, 116, 3585-3585.	0.6	0
114	Immune Phenotyping and Naive T Cells as a Predictor of Response to Therapy In Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 1362-1362.	0.6	0
115	Infectious Complications In a Prospective Cohort of Community Based Newly Diagnosed Patients with Chronic Lymphocytic Leukemia (CLL).. Blood, 2010, 116, 4610-4610.	0.6	0
116	Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients,. Blood, 2011, 118, 3903-3903.	0.6	0
117	In Patients Newly Diagnosed with Chronic Lymphocytic Leukemia the Absolute Monocyte Count At Presentation Is Directly Associated with Disease Progression Independently From Rai Staging or Cytogenetics. Blood, 2011, 118, 2835-2835.	0.6	0
118	The Prevalence of Serious Infectious Complications in a Cohort of Non-Referred Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. Blood, 2011, 118, 4610-4610.	0.6	0
119	Very High Risk CLL Characterized by a "Double Hit" Clone with Both 11q22 and 17p13 Deletion.. Blood, 2012, 120, 2486-2486.	0.6	0
120	Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan: A Phase I Clinical Trial. Blood, 2012, 120, 1792-1792.	0.6	0
121	Clinical Utility of PET/CT Scanning in Patients with Chronic Lymphocytic Leukemia. Blood, 2012, 120, 3903-3903.	0.6	0
122	Transformation of Chronic Lymphocytic Leukemia Into Diffuse Large B-Cell Lymphoma (Richter's) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 2	0.6	0
123	Analysis of Stem Cell Transplant Referral in a Cohort of Newly Diagnosed Chronic Lymphocytic Leukemia Patients. Blood, 2012, 120, 4252-4252.	0.6	0
124	An Effective and Tolerable Chemoimmunotherapy Regimen For Relapsed/Refractory and Very-High Risk Chronic Lymphocytic Leukemia Combining Alemtuzumab With Pentostatin and Low Dose Rituximab. Blood, 2013, 122, 1641-1641.	0.6	0
125	The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087) Tj ETQq1 1 0.784314 rgBT/Overl	0.6	0
126	Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies.. Journal of Clinical Oncology, 2018, 36, 6577-6577.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 2640-2640.	0.6	0